Arctic Vision, a  Shanghai ophthalmology company, was approved to start a China Phase III trial of a novel therapy for nearsightedness caused by age-related hardening of the lens. ARVN003 is pilocapine, a known treatment for temporary improvement of nearsightedness, that is administered by Optejet®, a proprietary micro-dosing device. Optejet delivers about 20% of an eye drop, preventing overdosing. In 2020, Arctic acquired China rights to the product from Eyenovia, a US biopharma. Earlier this year, Arctic completed a $100 million B round to expand its in-licensed portfolio. More details.... Share this with colleagues: // //